샘플 요청 목록

 카트 문의
시장보고서
상품코드
1759999

결합 조직병 치료 시장 - 성장, 전망, 경쟁 분석(2025-2033년)

Connective Tissue Disease Treatment Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 190 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

결합 조직병 치료 시장은 자가면역질환 및 염증성 결합조직질환의 유병률 증가와 효과적인 장기 치료에 대한 수요 증가로 인해 2025-2033년 예측기간 중 연평균 5.8%의 성장률을 보일 것으로 예측됩니다. 결합조직 질환의 치료에는 전신성 홍반성 루푸스, 류마티스 관절염, 전신성 경화증과 같은 질환이 포함되며, 면역 조절, 항염증 관리, 증상 완화가 필요합니다. 이 시장에서 일반적으로 사용되는 약물은 운동 기능을 개선하고 통증을 완화하며 장기적인 장기 장애를 예방합니다. 생물제제, 표적 저분자 약물, 개인 맞춤형 요법의 개발은 의료 시스템이 첨단 전문화된 치료로 이동함에 따라 이 산업을 계속 형성하고 있습니다.

시장 성장 촉진요인

표적 면역 조절 요법에 대한 수요 증가

면역 억제제 및 기타 표적 치료제에 대한 수요는 모든 지역에서 증가하고 있으며, 인식의 향상과 진단 능력의 확산에 따라 증가하고 있습니다. 의료진과 환자 모두 이러한 치료법이 자가면역 과정으로 인한 장기적인 손상을 줄이는 중요한 수단임을 인식하고 있습니다. 특히 코르티코스테로이드 절약 전략과 생물제제에 대한 연구의 급속한 발전은 이러한 치료법의 채택을 촉진하고 환자층을 확대하는 데 기여하고 있습니다.

조기 진단과 맞춤형 의료에 대한 중요성 증대

더 나은 진단과 의료 서비스 접근성을 통한 결합조직 질환의 조기 발견이 시장 도입을 촉진하고 있습니다. 의사와 연구자들은 바이오마커를 활용하여 환자 개개인의 필요에 맞는 치료를 하고 결과를 개선하는 맞춤 의료를 지향하고 있습니다. 특히 부신피질 스테로이드, 면역억제제, 신규 생물제제 개선에 중점을 둔 연구개발에 대한 민관 투자 증가는 장기적인 기술 혁신을 지원하고 있습니다.

안전하고 효과적인 장기 치료에 대한 수요 증가

결합조직질환은 만성적이고 진행성 질환이기 때문에 치료제의 장기적인 내약성과 안전성이 중요한 고려사항입니다. 일반적으로 경증에서 중등도의 경우 편의성과 비용 효율성 측면에서 경구용 약물이 선호되며, 신속한 개입이나 생물학적 치료가 필요한 중증의 경우 주사제가 권장되는 경우가 많습니다. 현재 진행 중인 제품 개선은 이러한 요구사항에 대응하는 것이며, 더 많은 환자들이 더 일찍 치료를 시작함에 따라 시장은 꾸준히 성장할 것입니다.

시장 성장 억제요인

만성 치료로 인한 부작용과 안전성 우려

큰 발전에도 불구하고 코르티코스테로이드와 면역억제제의 장기 치료는 감염, 장기 독성, 골다공증과 같은 심각한 부작용을 유발할 수 있습니다. 특히 환자가 불쾌한 부작용과 고비용을 경험하는 경우, 치료 순응도가 떨어질 수 있습니다. 또한 일부 첨단 치료법은 정기적인 주사와 전문적인 모니터링이 필요한데, 특히 의료 인프라가 부족한 농촌 지역이나 신흥 경제국에서는 접근성 및 비용 측면에서 문제가 될 수 있습니다.

의약품 유형별 시장 세분화

약물 유형별로는 면역억제제, 부신피질 스테로이드, 비스테로이드성 항염증약, 항말라리아제, 기타 약물 유형이 포함되며, 2024년에는 면역억제제가 중증 염증성 질환의 예방 및 관해 유지에 효과적이라는 점에서 시장을 장악할 것으로 예측됩니다. 부신피질 스테로이드는 급성 재발을 관리하기 위한 1차 선택 약물로 계속해서 중요한 역할을 할 것입니다. 항말라리아제, 특히 하이드록시클로로퀸은 경증 루푸스 및 기타 염증성 질환의 관리에 도움이 되고 있습니다. 새로운 생물제제 및 저분자를 포함한 다른 약물 유형은 규제 당국의 승인을 받으면서 보다 개인화된 선택이 가능해짐에 따라 강력한 성장을 보일 것으로 예측됩니다.

투여 경로별 시장 세분화

투여 경로별 부문은 경구제와 주사제로 구성됩니다. 경구용 치료제는 외래 치료에서의 광범위한 사용, 자가 투여의 용이성, 비용 우위로 인해 2024년 시장을 주도했습니다. 경구용 면역억제제와 코르티코스테로이드는 장기적인 질병 조절이 필요한 안정된 환자에게 여전히 표준 치료법입니다. 주사제 부문은 환자의 편의성과 복약 순응도를 향상시키는 생물제제 및 자가 주사 장비의 사용 증가로 인해 2025-2033년 더 높은 CAGR을 나타낼 것으로 예측됩니다. 또한 주사제는 더 빠른 효능으로 인해 특히 류마티스 및 전문 의료 분야에서 중등도에서 중증의 질병 프로파일에 적합한 선택이 되고 있습니다.

지역별 동향

북미는 탄탄한 의료 시스템, 결합조직 질환에 대한 인식 증가, 풍부한 상환 정책, 생물제제의 높은 채택률에 힘입어 2024년 세계 시장을 주도할 것으로 예측됩니다. 유럽은 독일, 프랑스, 영국과 같은 국가에서 부신피질 스테로이드와 면역억제제가 널리 사용되고 있으며, 잘 구축된 의료 네트워크와 부신피질 스테로이드와 면역억제제의 광범위한 사용으로 인해 근소한 차이로 그 뒤를 따랐습니다. 아시아태평양은 특히 중국, 인도, 한국, 일본에서 의료 인프라가 개선되고 조기 치료 옵션에 대한 인식이 높아짐에 따라 2025-2033년 가장 높은 CAGR로 성장할 것으로 예측됩니다. 가처분 소득 증가와 의료 현대화에 대한 투자 증가도 이 지역의 전망을 지원하고 있습니다. 라틴아메리카와 중동 및 아프리카는 점진적인 의료 정책 개혁과 환자 수 증가에 힘입어 장기적인 잠재력을 지닌 신흥 시장입니다.

경쟁사 동향

결합 조직병 치료제 시장은 경쟁이 치열하며, 주요 기업은 기술 혁신, R&D 투자, 다양한 제품 포트폴리오를 통해 시장을 공략하고 있습니다. 이 시장에 진출한 주요 기업으로는 애브비, 암젠, 애저리티 파마슈티컬스, 베링거인겔하임, 일라이 릴리, 글락소 스미스클라인, 인제나스 파마슈티컬스, 얀센, 머크, 노바티스, 화이자, 사노피, 사노피, 베링거인겔하임, 머크, 노바티스, 화이자, 사노피, 사노피, 베링거인겔하임, 베링거인겔하임, 베링거인겔하임, 베링거인겔하임, 베링거인겔하임, 베링거인겔하임 머크, 노바티스, 화이자, 사노피, 사노피, 테바 파마슈티컬스 등이 있습니다. 애브비와 얀센은 탄탄한 생물제제 포트폴리오, 세계 판매망, 지속적인 파이프라인 혁신으로 강력한 리더십을 유지하고 있습니다. 노바티스, 화이자, 일라이 릴리는 시장에서의 입지를 강화하기 위해 첨단 면역치료제와 바이오시밀러에 지속적으로 집중하고 있습니다. 암젠과 베링거인겔하임은 전략적 파트너십과 새로운 제형을 활용하여 장기적인 안전성과 효능을 향상시키고 있습니다. 애브비, 인제나스, 테바 파마슈티컬과 같은 기업도 비용 효율적인 제네릭 의약품과 바이오시밀러 의약품의 선택권을 강조하며 시장 규모를 확대하고 있습니다. 경쟁 환경은 더 많은 생물제제 승인, 맞춤형 의료에 대한 수요 증가, 전략적 제휴로 인해 더욱 치열해질 것으로 예상되며, 각 회사는 전문화된 제품, 지속가능성에 대한 노력, 더 넓은 지역적 범위로 차별화를 꾀할 수 있을 것으로 보입니다.

목차

제1장 서문

  • 리포트 내용
    • 리포트의 목적
    • 대상자
    • 주요 제공
  • 시장 세분화
  • 조사 방법
    • 단계 I - 2차 조사
    • 단계 II - 1차 조사
    • 단계 III - 전문가 패널 리뷰
    • 전제조건
    • 채택한 어프로치

제2장 개요

제3장 결합 조직병 치료 시장 : 경쟁 분석

  • 주요 벤더의 시장 포지셔닝
  • 벤더가 채택한 전략

제4장 결합 조직병 치료 시장 : 거시 분석과 시장 역학

  • 서론
  • 세계의 결합 조직병 치료 시장 금액 2023-2033년
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 촉진요인과 억제요인의 영향 분석
  • Porter's Five Forces 모델
    • 공급업체 파워
    • 바이어 파워
    • 대체품의 위협
    • 신규 진출업체의 위협
    • 경쟁 기업 간 경쟁 관계
  • PESTEL 분석
    • 정치정세
    • 경제정세
    • 테크놀러지 상황
    • 법적인 상황
    • 사회 상황

제5장 결합 조직병 치료 시장 : 질환 유형별 2023-2033년

  • 시장 개요
  • 성장·매출 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 자가면역질환
      • 류마티스 관절염
      • 경피증
      • 혼합성 결합 조직병
    • 유전성 질환

제6장 결합 조직병 치료 시장 : 약제 유형별 2023-2033년

  • 시장 개요
  • 성장·매출 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 면역억제제
    • 코르티코스테로이드
    • NSAIDs
    • 항말라리아약
    • 기타 약제 유형

제7장 결합 조직병 치료 시장 : 투여 경로별 2023-2033년

  • 시장 개요
  • 성장·매출 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 경구
    • 주사제

제8장 결합 조직병 치료 시장 : 유통 채널별 2023-2033년

  • 시장 개요
  • 성장·매출 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제9장 북미의 결합 조직병 치료 시장 2023-2033년

  • 시장 개요
  • 결합 조직병 치료 시장 : 질환 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 약제 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 투여 경로별 2023-2033년
  • 결합 조직병 치료 시장 : 유통 채널별 2023-2033년
  • 결합 조직병 치료 시장 : 지역별 2023-2033년
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제10장 영국과 유럽연합의 결합 조직병 치료 시장 2023-2033년

  • 시장 개요
  • 결합 조직병 치료 시장 : 질환 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 약제 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 투여 경로별 2023-2033년
  • 결합 조직병 치료 시장 : 유통 채널별 2023-2033년
  • 결합 조직병 치료 시장 : 지역별 2023-2033년
    • 영국과 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제11장 아시아태평양의 결합 조직병 치료 시장 2023-2033년

  • 시장 개요
  • 결합 조직병 치료 시장 : 질환 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 약제 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 투여 경로별 2023-2033년
  • 결합 조직병 치료 시장 : 유통 채널별 2023-2033년
  • 결합 조직병 치료 시장 : 지역별 2023-2033년
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제12장 라틴아메리카의 결합 조직병 치료 시장 2023-2033년

  • 시장 개요
  • 결합 조직병 치료 시장 : 질환 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 약제 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 투여 경로별 2023-2033년
  • 결합 조직병 치료 시장 : 유통 채널별 2023-2033년
  • 결합 조직병 치료 시장 : 지역별 2023-2033년
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제13장 중동 및 아프리카의 결합 조직병 치료 시장 2023-2033년

  • 시장 개요
  • 결합 조직병 치료 시장 : 질환 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 약제 유형별 2023-2033년
  • 결합 조직병 치료 시장 : 투여 경로별 2023-2033년
  • 결합 조직병 치료 시장 : 유통 채널별 2023-2033년
  • 결합 조직병 치료 시장 : 지역별 2023-2033년
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제14장 기업 개요

  • AbbVie
  • Amgen
  • Azurity Pharmaceuticals
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Ingenus Pharmaceutical
  • Janssen Pharmaceutical
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • 기타 주요 기업
KSA 25.07.09

The connective tissue disease treatment market is projected to grow at a CAGR of 5.8% during the forecast period 2025 to 2033, driven by the increasing prevalence of autoimmune and inflammatory connective tissue disorders and rising demand for effective long-term therapies. Treatments for connective tissue diseases, which include conditions like systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis, require immunomodulation, anti-inflammatory management, and symptomatic relief. Medications commonly used in this market improve mobility, reduce pain, and prevent long-term organ damage. Developments in biologics, targeted small-molecule drugs, and personalized regimens continue to shape the industry as healthcare systems shift toward advanced and specialized care.

Market Drivers

Growing Demand for Targeted Immunomodulating Therapies

As awareness improves and diagnostic capabilities become more widespread, demand for immunosuppressants and other targeted therapies has increased across all regions. Providers and patients alike recognize these treatments as vital tools in mitigating long-term damage from autoimmune processes. Rapid advances in research, especially surrounding corticosteroid-sparing strategies and biologics, have fueled the adoption of these therapies and expanded the patient base.

Increasing Emphasis on Early Diagnosis and Personalized Medicine

Earlier detection of connective tissue diseases through better diagnostics and access to healthcare is boosting market uptake. Physicians and researchers have been moving toward personalized medicine, leveraging biomarkers to match therapies to individual patient needs and improve outcomes. Rising public and private investment in R&D, especially focused on refining corticosteroids, immunosuppressants, and novel biologics, supports long-term innovation.

Rising Demand for Safe and Effective Long-term Therapies

Given the chronic and progressive nature of connective tissue diseases, long-term tolerability and safety of therapies are significant considerations. Oral agents are generally preferred for mild to moderate cases due to convenience and cost-effectiveness, while injectables are often recommended for severe presentations needing rapid intervention or biologic therapies. Ongoing product improvements address these requirements, allowing the market to grow steadily as more patients initiate therapy at earlier stages.

Market Restraint

Side Effects and Safety Concerns of Chronic Therapy

Despite significant progress, long-term treatment with corticosteroids and immunosuppressants can result in serious adverse effects such as infections, organ toxicity, or osteoporosis. This may lead to poor adherence, especially when patients experience unpleasant side effects or high costs. Moreover, some advanced therapies require regular injections or specialized monitoring, which can pose access and cost challenges, especially in rural or developing economies with limited healthcare infrastructure.

Market Segmentation by Drug Type

The Drug Type segment includes Immunosuppressants, Corticosteroids, NSAIDs, Antimalarial Drugs, and Other Drug Types. In 2024, immunosuppressants dominated the market due to their efficacy in preventing severe inflammatory damage and maintaining remission. Corticosteroids continue to play a critical role as first-line therapy for managing acute flares. NSAIDs offer symptomatic relief for pain and swelling in less aggressive cases, while antimalarials, especially hydroxychloroquine, help manage milder forms of lupus and other inflammatory conditions. Other drug types, including emerging biologics and small molecules, are anticipated to show strong growth as more personalized options receive regulatory approvals.

Market Segmentation by Route of Administration

The Route of Administration segment comprises Oral and Injectables. Oral therapies led the market in 2024 owing to their broad use in outpatient care, ease of self-administration, and cost advantages. Oral immunosuppressants and corticosteroids remain standard practice for stable patients needing long-term disease control. The injectables segment is projected to register a higher CAGR from 2025 to 2033 due to the increased use of biologic agents and self-injectable devices that improve patient convenience and medication adherence. Injectable options also support more rapid efficacy and are becoming the preferred choice for moderate to severe disease profiles, especially in rheumatology and specialized care settings.

Geographic Trends

North America led the global market in 2024, driven by a strong healthcare system, greater awareness of connective tissue disorders, robust reimbursement policies, and high adoption of biologic therapies. Europe followed closely due to its established healthcare networks and the widespread use of corticosteroids and immunosuppressants across countries like Germany, France, and the UK. Asia Pacific is projected to grow at the highest CAGR during 2025 to 2033 as healthcare infrastructure improves, especially in China, India, South Korea, and Japan, and public awareness of early treatment options expands. Rising disposable incomes and increasing investments in healthcare modernization also support the regional outlook. Latin America and the Middle East & Africa remain emerging markets with substantial long-term potential driven by gradual healthcare policy reforms and rising patient volumes.

Competitive Trends

The connective tissue disease treatment market is competitive, with leading pharmaceutical companies leveraging innovation, R&D investments, and broad product portfolios. Major companies active in the market include AbbVie, Amgen, Azurity Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Ingenus Pharmaceutical, Janssen Pharmaceutical, Merck, Novartis, Pfizer, Sanofi, and Teva Pharmaceutical. AbbVie and Janssen Pharmaceutical maintain strong leadership owing to their well-established biologics portfolios, global distribution networks, and continuous pipeline innovation. Novartis, Pfizer, and Eli Lilly continue to focus on advanced immunotherapies and biosimilar options to strengthen their market position. Amgen and Boehringer Ingelheim leverage strategic partnerships and novel drug formulations to enhance long-term safety and efficacy. Other companies like Azurity, Ingenus, and Teva Pharmaceutical expand reach by emphasizing cost-effective generic and biosimilar options. The competitive environment is expected to intensify with more biologics approvals, increased demand for personalized medicine, and strategic collaborations, allowing companies to differentiate themselves through specialized offerings, sustainability initiatives, and broader geographic reach.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Connective Tissue Disease Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Connective Tissue Disease Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

  • Disease Type
  • Autoimmune diseases
  • Rheumatoid arthritis
  • Scleroderma
  • Mixed connective tissue disease
  • Genetic disorders
  • Drug Type
  • Immunosuppressants
  • Corticosteroids
  • NSAIDs
  • Antimalarial drugs
  • Other drug types
  • Route of Administration
  • Oral
  • Injectables
  • Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Connective Tissue Disease Treatment market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Connective Tissue Disease Treatment market?
  • Which is the largest regional market for Connective Tissue Disease Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Connective Tissue Disease Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Connective Tissue Disease Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Connective Tissue Disease Treatment Market
  • 2.2. Global Connective Tissue Disease Treatment Market, By Disease Type, 2024 (US$ Million)
  • 2.3. Global Connective Tissue Disease Treatment Market, By Drug Type, 2024 (US$ Million)
  • 2.4. Global Connective Tissue Disease Treatment Market, By Route of Administration, 2024 (US$ Million)
  • 2.5. Global Connective Tissue Disease Treatment Market, By Distribution Channel, 2024 (US$ Million)
  • 2.6. Global Connective Tissue Disease Treatment Market, By Geography, 2024 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2024

3. Connective Tissue Disease Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Connective Tissue Disease Treatment Market Vendors
  • 3.2. Strategies Adopted by Connective Tissue Disease Treatment Market Vendors

4. Connective Tissue Disease Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Connective Tissue Disease Treatment Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. Porter's Five Force Model
    • 4.5.1. Supplier Power
    • 4.5.2. Buyer Power
    • 4.5.3. Threat Of Substitutes
    • 4.5.4. Threat Of New Entrants
    • 4.5.5. Competitive Rivalry
  • 4.6. PESTEL Analysis
    • 4.6.1. Political Landscape
    • 4.6.2. Economic Landscape
    • 4.6.3. Technology Landscape
    • 4.6.4. Legal Landscape
    • 4.6.5. Social Landscape

5. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Autoimmune diseases
      • 5.3.1.1. Rheumatoid arthritis
      • 5.3.1.2. Scleroderma
      • 5.3.1.3. Mixed connective tissue disease
    • 5.3.2. Genetic disorders

6. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Immunosuppressants
    • 6.3.2. Corticosteroids
    • 6.3.3. NSAIDs
    • 6.3.4. Antimalarial drugs
    • 6.3.5. Other drug types

7. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 7.3. Market Segmentation
    • 7.3.1. Oral
    • 7.3.2. Injectables

8. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 8.3. Market Segmentation
    • 8.3.1. Hospital pharmacies
    • 8.3.2. Retail pharmacies
    • 8.3.3. Online pharmacies

9. North America Connective Tissue Disease Treatment Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
  • 9.3. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
  • 9.4. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 9.5. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 9.6. Connective Tissue Disease Treatment Market: By Region, 2023-2033, USD (Million)
    • 9.6.1. North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 9.6.1.1.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 9.6.1.1.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 9.6.1.1.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 9.6.1.2.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 9.6.1.2.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 9.6.1.2.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 9.6.1.3.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 9.6.1.3.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 9.6.1.3.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

10. UK and European Union Connective Tissue Disease Treatment Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
  • 10.3. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
  • 10.4. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 10.5. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 10.6. Connective Tissue Disease Treatment Market: By Region, 2023-2033, USD (Million)
    • 10.6.1. UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 10.6.1.1.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 10.6.1.1.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.1.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 10.6.1.2.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 10.6.1.2.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.2.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 10.6.1.3.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 10.6.1.3.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.3.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 10.6.1.4.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 10.6.1.4.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.4.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 10.6.1.5.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 10.6.1.5.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.5.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 10.6.1.6.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 10.6.1.6.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.6.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

11. Asia Pacific Connective Tissue Disease Treatment Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
  • 11.3. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
  • 11.4. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 11.5. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 11.6. Connective Tissue Disease Treatment Market: By Region, 2023-2033, USD (Million)
    • 11.6.1. Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 11.6.1.1.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 11.6.1.1.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.1.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 11.6.1.2.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 11.6.1.2.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.2.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 11.6.1.3.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 11.6.1.3.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.3.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 11.6.1.4.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 11.6.1.4.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.4.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 11.6.1.5.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 11.6.1.5.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.5.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 11.6.1.6.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 11.6.1.6.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.6.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

12. Latin America Connective Tissue Disease Treatment Market, 2023-2033, USD (Million)

  • 12.1. Market Overview
  • 12.2. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
  • 12.3. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
  • 12.4. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 12.5. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 12.6. Connective Tissue Disease Treatment Market: By Region, 2023-2033, USD (Million)
    • 12.6.1. Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 12.6.1.1.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 12.6.1.1.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.6.1.1.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 12.6.1.2.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 12.6.1.2.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.6.1.2.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 12.6.1.3.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 12.6.1.3.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.6.1.3.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

13. Middle East and Africa Connective Tissue Disease Treatment Market, 2023-2033, USD (Million)

  • 13.1. Market Overview
  • 13.2. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
  • 13.3. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
  • 13.4. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 13.5. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 13.6. Connective Tissue Disease Treatment Market: By Region, 2023-2033, USD (Million)
    • 13.6.1. Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 13.6.1.1.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 13.6.1.1.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.6.1.1.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 13.6.1.2.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 13.6.1.2.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.6.1.2.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Connective Tissue Disease Treatment Market: By Disease Type, 2023-2033, USD (Million)
        • 13.6.1.3.2. Connective Tissue Disease Treatment Market: By Drug Type, 2023-2033, USD (Million)
        • 13.6.1.3.3. Connective Tissue Disease Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.6.1.3.4. Connective Tissue Disease Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

14. Company Profile

  • 14.1. AbbVie
  • 14.2. Amgen
  • 14.3. Azurity Pharmaceuticals
  • 14.4. Boehringer Ingelheim
  • 14.5. Eli Lilly and Company
  • 14.6. GlaxoSmithKline
  • 14.7. Ingenus Pharmaceutical
  • 14.8. Janssen Pharmaceutical
  • 14.9. Merck
  • 14.10. Novartis
  • 14.11. Pfizer
  • 14.12. Sanofi
  • 14.13. Other Notable Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제